<DOC>
	<DOCNO>NCT00682370</DOCNO>
	<brief_summary>Heme oxygenase 1 ( HO-1 ) serve protective gene . It show one factor modulate HO-1 activity genetic variation HO-1 gene ( functional GT length polymorphism promotor region ) . Heme arginate strong inducer HO-1 show several animal experimental study . The aim clinical trial evaluate HO-1 stimulation heme arginate healthy human .</brief_summary>
	<brief_title>Effects Heme Arginate Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Signed informed consent prior studymandated procedure . Male age 18 45 year ( inclusive ) screening . No clinically significant finding physical examination screening . Body mass index ( BMI ) 18 28 kg/m2 ( inclusive ) screening . 12lead ECG without clinically relevant abnormality screen . Hematology , clinical chemistry , urinalysis test result deviate normal range clinically relevant extent screening . Negative result urine drug screen screen . Ability communicate well investigator , local language , understand comply requirement study . Known hypersensitivity study drug excipients drug formulation . Treatment another investigational drug within 3 month prior screen . History clinical evidence alcoholism drug abuse within 3year period prior screen . History clinical evidence disease and/or existence surgical medical condition , might interfere absorption , distribution , metabolism excretion study drug . Smoking within last 3 month prior screen . Previous treatment prescribe OTC medication ( include herbal medicine St John 's Wort ) within 2 week prior screen . Loss 250 ml blood within 3 month prior screen . Positive result hepatitis serology , except vaccinated subject , screen . Positive result HIV serology screen . Presumed noncompliance . Legal incapacity limit legal capacity screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>